Improved understanding of the molecular causes of leukaemia is altering the approach to management. Acute myeloid leukaemia is managed with chemotherapy according to the patient's prognostic factors, but stem cell transplantation may be an option. Imatinib is now available for the treatment of chronic myeloid leukaemia, but whether it should be preferred over transplantation is uncertain. When chronic lymphocytic leukaemia progresses, it can be managed with chemotherapy, in which fludarabine has an increasing role.
Introduction
adults. This is due largely to improved understanding of the molecular basis of these diseases. Improvements in supportive care, the introduction of targeted therapies and increasing use of non-myeloablative conditioning regimens for allogeneic stem cell transplantation have all transformed the treatment of patients with leukaemia. This means that more patients may be offered treatment and that more can be expected to survive for longer periods.
Acute myeloid leukaemia
The incidence of acute myeloid leukaemia increases with age.
It accounts for 80% of adult acute leukaemias. Most patients present with clinical features of bone marrow failure such as recurrent infection, bleeding and fatigue. Many experience bone pain, weight loss, sweats and fevers. While the majority have no predisposing factors to explain the development of the disease, some patients will have a history of a haematological disorder (such as myelodysplasia) or exposure to cytotoxic drugs.
Studies of outcomes after treatment for acute myeloid leukaemia have shown that the most important prognostic factor is the type of cytogenetic abnormality present at diagnosis. 1 The combination of a synthetic retinoid (all-trans-retinoic acid (tretinoin)) and the anthracycline idarubicin, induces maturation and apoptosis of leukaemic cells. This leads to remission in most cases and to long-term disease-free survival in over 70% of patients. 3 Arsenic trioxide has also shown promise in the treatment of de novo and relapsed/refractory disease. Its role in therapy is the subject of intense research interest.
Chronic myeloid leukaemia
Chronic myeloid leukaemia accounts for 7-15% of all adult leukaemias. It is thought to result from the clonal transformation of a haematopoietic stem cell and is historically significant because it was the first disease in which a specific chromosomal abnormality was directly linked to pathogenesis.
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